Jentashapir Journal of Health Research

Published by: Kowsar

Comparison of the Effects of CinnoVex, Rebif and Betaferon on a Expanded Disability Status Scale of Patients With Multiple Sclerosis

Nastaran Madjdinasab 1 , * , Seyed Ehsan Mohammadiany Nejad 1 , Shahram Tarahomi 1 , Fatemeh Sadr 1 and Mohammad Bahadoram 1
Authors Information
1 Department of Neurology, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IR Iran
Article information
  • Jentashapir Journal of Health Research: June 01, 2015, 6 (3); e29201
  • Published Online: June 27, 2015
  • Article Type: Research Article
  • Received: November 12, 2014
  • Accepted: December 28, 2014
  • DOI: 10.5812/jjhr.6(3)2015.29201

To Cite: Madjdinasab N, Mohammadiany Nejad S E, Tarahomi S, Sadr F, Bahadoram M. Comparison of the Effects of CinnoVex, Rebif and Betaferon on a Expanded Disability Status Scale of Patients With Multiple Sclerosis, Jentashapir J Health Res. 2015 ; 6(3):e29201. doi: 10.5812/jjhr.6(3)2015.29201.

Copyright © 2015, Ahvaz Jundishapur University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Mazdeh M, Afzali S, Jaafari MR. The therapeutic effect of Avonex, Rebif and Betaferon on EDSS and relapse in multiple sclerosis: a comparative study. Acta Med Iran. 2010; 48(2): 83-8[PubMed]
  • 2. Etemadifar M, Mazdeh M, Torabi HR, Ghaffarpour M, Azimian M, Salami S, et al. A report of multiple sclerosis patients treated by CinnoVex in Iran. Tehran Univ Med Sci. 2010; 68(1): 30-6
  • 3. Weinstock-Guttman B, Bakshi R. Combination therapy for multiple sclerosis: the treatment strategy of the future? CNS Drugs. 2004; 18(12): 777-92[DOI][PubMed]
  • 4. Ebers GC. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet. 1998; 352(9139): 1498-504[DOI]
  • 5. Pozzilli C, Prosperini L, Sbardella E, De Giglio L, Onesti E, Tomassini V. Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience. Neurol Sci. 2005; 26(4)-8
  • 6. Olek MJ, Dawson DM. Multiple sclerosis and other inflammatory demyelinating diseases of the central nervous system. 2004; : 1631-64
  • 7. Cottrell DA, Kremenchutzky M, Rice GPA, Koopman WJ, Hader W, Baskerville J, et al. The natural history of multiple sclerosis: A geographically based study. Brain. 1999; 122(4): 625-39
  • 8. Kremenchutzky M, Cottrell D, Rice G, Hader W, Baskerville J, Koopman W, et al. The natural history of multiple sclerosis: a geographically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation. Brain. 1999; 122 ( Pt 10): 1941-50[PubMed]
  • 9. IFNB Multiple Sclerosis Study Group . Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis I. Clinical results of a multicenter, randomized, double‐blind, placebo-controlled trial. Neurol. 1993; 43(4): 655
  • 10. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol. 1996; 39(3): 285-94[DOI][PubMed]
  • 11. Claire SR, Mark JT. Merritt's Neurology. 2005; : 958-60
  • 12. Etemadifar M, Janghorbani M, Shaygannejad V. Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis. Acta Neurol Scand. 2006; 113(5): 283-7[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments